S
Research Areas
Biography and Research Information
OverviewAI-generated summary
Syed Naqvi's research interests encompass a range of topics, including the application of machine learning in environmental science and healthcare, as well as clinical investigations in hematology-oncology. His work has explored the adsorption of microplastics by magnetic biochar and the development of fluorescence-based sensors for environmental monitoring. In the medical field, Naqvi has investigated postpartum HELLP syndrome with liver hematoma, the efficacy of self-expanding metal stents for malignant colon obstruction, and the impact of talquetamab on weight loss and dysgeusia in multiple myeloma patients. He also utilizes machine learning for microplastic identification from FTIR data and risk assessment of organic pollutants in honey. Naqvi has published 38 papers, with an h-index of 7 and 294 citations. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Hira Imad Cheema, Trilok Shrivastava, Ramya Bachu, and Tanvi H Patel.
Metrics
- h-index: 7
- Publications: 27
- Citations: 270
Selected Publications
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (2025)
-
Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (2025)
-
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)
-
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
-
Discontinuation of levothyroxine therapy in patients with subclinical hypothyroidism: a pilot randomized clinical trial (2025)
-
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024)
-
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024)
-
SAT145 Familial Renal Glycosuria - A Differential Diagnosis For Hypoglycemia (2023)
-
THU664 Discontinuation Of Low-dose Levothyroxine Therapy For Patients With Subclinical Hypothyroidism Is Feasible: A Pilot, Randomized, Double-blind, Placebo-controlled Trial (2023)
-
SAT173 Insulin Autoimmune Syndrome: A Rare Diagnosis With Unique Features (2023)
-
Self-expanding metal stents for the treatment of malignant colon obstruction from extra-colonic malignancy versus intra-colonic malignancy: a systematic review and meta-analysis (2023)
-
Overtreatment and Undertreatment with Thyroid Hormone Is Associated with Cardiovascular Mortality (2022)
Collaboration Network
Top Collaborators
Maurizio Zangari
University of Arkansas for Medical Sciences
7 shared publications
In database
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Showing 5 of 7 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
7 shared publications
In database
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Showing 5 of 7 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
7 shared publications
In database
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Showing 5 of 7 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
6 shared publications
In database
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.
Showing 5 of 6 shared publications
Samer Al Hadidi
University of Arkansas for Medical Sciences
6 shared publications
In database
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network.
Showing 5 of 6 shared publications
Sang Hyun Park
Korea University of Science and Technology (KR)
5 shared publications
- Recent advances and factors affecting the adsorption of nano/microplastics by magnetic biochar
- Fluorescence-based sensors for environmental monitoring of small hazardous molecules: Recent trends and future prospects
- Machine learning-driven microplastics identification using ensemble stacking with Extra Tree meta-models from FTIR data
- Spatial non-targeted screening and machine learning-based risk assessment of organic pollutants in honey from Bhakkar District, Pakistan
- Recent advances in hydrogels for adsorption and electrochemical detection of heavy metals
Asis Shrestha
University of Arkansas for Medical Sciences (US)
4 shared publications
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Khurram Shahzad
Korea Atomic Energy Research Institute (KR)
4 shared publications
- Fluorescence-based sensors for environmental monitoring of small hazardous molecules: Recent trends and future prospects
- Machine learning-driven microplastics identification using ensemble stacking with Extra Tree meta-models from FTIR data
- Spatial non-targeted screening and machine learning-based risk assessment of organic pollutants in honey from Bhakkar District, Pakistan
- Recent advances in hydrogels for adsorption and electrochemical detection of heavy metals
Hira Imad Cheema
University of Arkansas for Medical Sciences
3 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Kil To Chong
Jeonbuk National University (KR)
3 shared publications
- Machine learning-enhanced analysis of catalyst particle size effects and performance prediction of platinum on carbon electrocatalysts
- Machine learning-driven microplastics identification using ensemble stacking with Extra Tree meta-models from FTIR data
- WBML-PV: Window-based machine learning for ultra-short-term photovoltaic power forecasting
Abrar Hussain
Korea Atomic Energy Research Institute (KR)
3 shared publications
- Machine learning-driven microplastics identification using ensemble stacking with Extra Tree meta-models from FTIR data
- Spatial non-targeted screening and machine learning-based risk assessment of organic pollutants in honey from Bhakkar District, Pakistan
- Recent advances in hydrogels for adsorption and electrochemical detection of heavy metals
Ramya Bachu
Winthrop Rockefeller Foundation
2 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Anup Kumar Trikannad
Winthrop Rockefeller Foundation (US)
2 shared publications
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Trilok Shrivastava
Winthrop Rockefeller Foundation
2 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Marah Alzubi
University of Jordan (JO)
2 shared publications
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Similar Researchers
Based on overlapping research topics
Naveen Yarlagadda
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Multiple Myeloma Research and Treatments
Meta-analysis and systematic reviews
Justin J. Thomas
University of Arkansas for Medical Sciences
Machine Learning Applications
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Abdul Rafae
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Multiple Myeloma Research and Treatments
Meta-analysis and systematic reviews
Michaelmary Chukwu
University of Arkansas at Fayetteville
Machine Learning Applications
Environmental Monitoring
Meta-analysis and systematic reviews
Hira Imad Cheema
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Multiple Myeloma Research and Treatments
Meta-analysis and systematic reviews
Liyan Mazahreh
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Multiple Myeloma Research and Treatments
Meta-analysis and systematic reviews